![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/03/2908350/0/en/Spero-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/03/2892586/0/en/Spero-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/16/2883860/0/en/Spero-Therapeutics-to-Participate-in-H-C-Wainwright-Annual-BioConnect-Investor-Conference.html
https://www.globenewswire.com/news-release/2024/05/15/2882891/0/en/Spero-Therapeutics-Announces-First-Quarter-2024-Operating-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com/news-release/2024/05/08/2877754/0/en/Spero-Therapeutics-to-Report-First-Quarter-2024-Financial-Results-and-Provide-Business-Update-on-Wednesday-May-15-2024.html
https://www.globenewswire.com/news-release/2024/05/01/2873644/0/en/Spero-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
https://www.globenewswire.com//news-release/2024/03/13/2845822/0/en/Spero-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2023-Operating-Results-and-Provides-a-Business-Update.html
https://www.globenewswire.com//news-release/2024/03/06/2841401/0/en/Spero-Therapeutics-to-Provide-Business-Update-and-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-Wednesday-March-13-2024.html
https://www.globenewswire.com//news-release/2024/02/28/2836936/0/en/Spero-Therapeutics-Announces-Clearance-of-IND-for-SPR206-to-Treat-MDR-Gram-negative-Bacterial-Infections.html
https://www.globenewswire.com//news-release/2024/02/26/2835109/0/en/Spero-Therapeutics-to-Present-at-Cowen-s-44th-Annual-Healthcare-Conference.html